

40/02/01
U.S. PTO

4-23-01

A
BOX
self

Berlex Laboratories, Inc.
15049 San Pablo Avenue
PO Box 4099
Richmond, CA 94804-0099

**BOX PATENT APPLICATION
ASSISTANT COMMISSIONER FOR PATENTS
Washington, DC 20231**

Atty. Docket No. 51831AUSM1

"Express Mail" Label No. EL414974440US
Date of Deposit April 20, 2001

I hereby certify that this is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to:

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

By: Grace J. Smith, Jr.

jc903 U.S. PTO
09/838785
04/20/01

Sir:

Transmitted herewith for filing under 37 CFR §1.53(b) is the
[X] patent application [] continuation patent application,
[] divisional patent application or [] continuation-in-part
patent application of

Inventors Identifier: Ted LAU, Richard J. LIN, Deborah PARKES, Gordon PARRY, Douglas W. SCHNEIDER, Renate STEINBRECHER, Pamela Toy VAN HEUIT, and John WU

For: DNA ENCODING A NOVEL PROST 03 POLYPEPTIDE

[] This application claims priority from each of the following Application No./filing dates:

US Serial No. _____ / _____ the disclosure(s) of which is (are) incorporated by reference.

[] Please amend this application by adding the following before the first sentence: -This application is a [] continuation [] division of and claims the benefit of U.S. Application No. _____ filed _____, the disclosure of which is incorporated by reference.--
[X] The benefit under 35 U.S.C. Section 119 is claimed of the filing date of: U.S. Provisional Application No. 60/200,065, filed April 27, 2000.

Enclosed are:

[X] 12 sheets of [] formal [6] informal drawings(s) and 49 pages of specifications including description, claims and abstract.
[X] Transmittal of Sequence Listing
[X] 12 pages of Sequence Listing with computer readable disk.
[] An assignment of the invention to _____.
[X] A [] signed [X] unsigned Declaration and Power of Attorney.
[] A [] signed [] unsigned Declaration
[] A Power of Attorney by Assignee with Certificate Under 37 CFR Section 3.73(b).
[] A certified copy of a _____.
[X] Information Disclosure Statement under 37 CFR 1.97.
[] A petition to extend time to respond in the parent application
[] Notification of change of [] power of attorney [] correspondence address filed in prior application.
[] Please cancel claim(s) _____.
[] Preliminary Amendment
[X] Return postcard

(Col. 1) (Col. 2)

FOR:	NO FILED	NO EXTRA	RATE	FEE
BASIC FEE				\$710.00
TOTAL CLAIMS	38 - 20 =	* 18	x \$18.00 =	324.00
INDEPENDENT CLAIMS	10 - 3 =	* 7	X \$80.00 =	560.00
[] MULTIPLE DEPENDENT CLAIMS PRESENTED			= \$270.00 =	
* if the difference in Col. 1 is less than zero, enter "0" in Col. 2				TOTAL \$1594.00

[] There is no increase in the accompanying Preliminary Amendment in the number of independent, dependent or multiple dependent claims beyond those previously paid for.

Please charge Deposit Account 02-2117 as follows:

[X] Filing fee
[X] Any additional fees associated with this paper or
during the pendency of this application.
[] The issue fee set in 37 CFR 1.18 at or before mailing of the Notice
of Allowance, pursuant to 37 CFR 1.311(b).

Respectfully submitted,

Wendy L. Washtien

Wendy L. Washtien
Reg. No. 36,301
Patent Agent for Applicants

Telephone: 510 262-5411 Facsimile: 510 262-7095

Date: April 19, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC903 U.S. PRO
09/838785
04/20/01



In re Application of

Lau et al.

Serial No.: Not yet known

: Group Art Unit: Not yet known

Filed: Filed herewith

: Examiner: Not yet known

For DNA ENCODING A NOVEL PROST 03 POLYPEPTIDE

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231


Sir:

TRANSMITTAL OF SEQUENCE LISTING

Applicants hereby submit a Sequence Listing and a Sequence Listing in computer readable form (as required under 37 CFR §1.821-1.825).

Applicants' attorney attests that the information recorded in computer readable form is identical to the written "Sequence Listing", as required under 37 CFR §1.821(f). This submission introduces no new matter, since the enclosed sequences are identical to the sequences which were submitted in the original patent application.

Respectfully submitted,



Wendy L. Washtien, Ph.D.

Agent for Applicants

Reg. No. 36,301

Berlex Biosciences
15049 San Pablo Avenue
P.O. Box 4099
Richmond, CA 94804-0099
Telephone: (510) 262-5411
Fax: (510) 262-7095
Date: April 5, 2001